Hot on the heels of the latest complete response letter from the US Food and Drug Administration over its AVT02 proposed rival to Humira (adalimumab), biosimilars specialist Alvotech has appointed a new chief quality officer, just six months after the last replacement.
In October, Alvotech announced the appointment of Sarah Tanksley as chief quality officer, replacing Reem Malki who stepped down “for personal reasons.” (Also see "Who’s Hired? Alvotech Brings In New Quality Chief" - Generics Bulletin, 14 October, 2022.) This change came after Alvotech received a CRL from the FDA over the 100mg/ml high-concentration AVT02 candidate earlier in 2022